Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATYR PHARMA INC

3.28
+0.18005.81%
Volume:1.53M
Turnover:4.98M
Market Cap:291.46M
PE:-3.80
High:3.33
Open:3.07
Low:3.05
Close:3.10
Loading ...

Company Profile

Company Name:
ATYR PHARMA INC
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
61
Office Location:
10240 Sorrento Valley Road,Suite 300,San Diego,California,United States
Zip Code:
92121
Fax:
858 731 8394
Introduction:
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Directors

Name
Position
John K. Clarke
Chairman of the Board
Sanjay S. Shukla
President, Chief Executive Officer and Director
Jane A. Gross
Director
Jeffrey S. Hatfield
Director
Paul Schimmel
Director
Svetlana Lucas
Director
Timothy P. Coughlin
Director

Shareholders

Name
Position
Sanjay S. Shukla
President, Chief Executive Officer and Director
Jill M. Broadfoot
Chief Financial Officer
Nancy E. Denyes
General Counsel and Corporate Secretary